SinaInnovations Spotlights a New Era of Discovery
“We have learned that the impossible is possible, and advances are being made that we could not have imagined just a few years ago,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs,...
Department of Pharmacology and Systems Therapeutics Awarded More Than $31 Million in NIH Grants
Researchers at the Icahn School of Medicine at Mount Sinai have received more than $31 million from the National Institutes of Health (NIH) to create three new centers that will study how drugs interact with human cells to increase their effectiveness and decrease...
Potential New Drug and Clinical Trial: Sarcoidosis Goes “Modern” with Crowdsourcing
Developing new drugs for the treatment of sarcoidosis isn’t easy. First, the cause of sarcoidosis is unknown. Second, prednisone, a remarkably effective medication for the treatment of sarcoidosis, limited only by its adverse side effect profile, is tough to beat....
Cardiovascular Risk Factors May Lead to Early Brain Changes
Abnormalities in the structure and function of the brain can appear in people who are overweight, smoke, have diabetes, hypertension, elevated lipids, or metabolic syndrome before the other consequences of vascular risk factors—such as a heart attack or stroke—appear,...
Exploring the Impact of Anesthesia on the Elderly
A pioneering study now under way at the Mount Sinai Health System’s Translational and Molecular Imaging Institute is exploring why older patients often wake up from surgery disoriented and some experience cognitive deficits several months later. The study is being led...
Study Reveals Common Genetic Changes Are Significant in Autism
Genetic changes are responsible for roughly 60 percent of the risk for autism, and most of these variants are commonly found in the general population, according to a groundbreaking study led by Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center for Research...
Clinical Trial Now Available For Patients With HPV-positive Oropharyngeal Squamous Cell Carcinoma
A new therapeutic clinical trial is now available at Mount Sinai for patients with HPV-related oropharyngeal (tonsil and tongue base) cancer who are eligible to undergo robot-assisted surgery. This study tests a novel vaccine (ADXS11-001) that patients receive during...
Teaching Heart-Healthy Habits to High-Risk Children and Families
Icahn School of Medicine at Mount Sinai has received a $3.8 million grant from the American Heart Association (AHA) to promote cardiovascular health through early education and intervention programs targeting high-risk children and their parents in Harlem and the...
New Research Refutes Long-Held Antiviral Theory
A long-standing belief that mammals use the same potent antiviral molecules deployed by plants and invertebrates is being challenged by researchers at Icahn School of Medicine at Mount Sinai. Their findings, published in the July 10, 2014, issue of Cell Reports,...